TICKERNERD
Menu
ELMDELMDHealthcare · Medical Devices

ELMD Stock Forecast: Electromed, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$39
−1.37% on the day

The 3 Wall Street analysts covering Electromed, Inc. hold a median 12-month price target of $40 — +1.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$326.6M
Ticker Nerd rank
99 / 100
Median analyst target
$40
Analysts covering
3
Total return, dividends reinvested
1W
−4.3%
1M
−2.6%
YTD
+35.5%
1Y
+107.4%
From 52W high
−14.8%
From 52W low
+107.4%
$19
$46
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Electromed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Momentum
86
Issuance
82
Revisions
81
Volatility
81
Growth
79
Value
79
Size
60
Accruals
34

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (34): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26ELMDHigh $45Median $40Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $36Median $40High $45

The green dot is the last close — the median target sits +1.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 May 2026B. Riley SecuritiesMaintainsBuy—
12 Feb 2026Freedom BrokerMaintainsBuy—
19 Nov 2025Freedom BrokerMaintainsBuy—
13 Nov 2025Roth CapitalReiteratesBuy—
27 Aug 2025Lake StreetAssumesBuy$36
27 Aug 2025Roth CapitalMaintainsBuy—
22 July 2025Roth CapitalInitiatesBuy—
20 Feb 2025B. Riley SecuritiesInitiatesBuy—
11 May 2023EF HuttonReiteratesBuy—
16 Feb 2023EF HuttonMaintainsBuy—
15 Feb 2023Lake StreetMaintainsBuy—
28 Dec 2022Lake StreetAssumesBuy$20
6 Sept 2022EF HuttonInitiatesBuy—
5 Aug 2022Lake StreetInitiatesBuy—
24 Nov 2020Northland Capital MarketsInitiatesOutperform—
18 Oct 2019Dougherty & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ELMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Electromed, Inc. (ELMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.7×

Cheaper than 23% of US stocks

Price / sales
4.6×

Cheaper than 27% of US stocks

Price / book
6.6×

Cheaper than 16% of US stocks

EV / EBITDA
21.3×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
18.4%

Higher than 68% of US stocks

Earnings growth (YoY)
58.8%

Higher than 77% of US stocks

Gross margin
78.8%

Higher than 90% of US stocks

Operating margin
20.3%

Higher than 79% of US stocks

Net margin
14.1%

Higher than 76% of US stocks

Returns & dividend
Return on equity
21.7%

Higher than 83% of US stocks

Return on assets
14.9%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ELMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ELMDElectromed, Inc.$326.6M
99
VMDViemed Healthcare, Inc.$336.5M
96
TLSITriSalus Life Sciences, Inc.$315.2M
29
MOBIMobia Medical, Inc.$351.0M
2
RCELAVITA Medical, Inc.$306.8M
63
CVCapsoVision, Inc.$300.0M
20
CATXPerspective Therapeutics, Inc.$375.9M
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Electromed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELMD news & analysis

Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026

Business Wire · 11 Aug 2026neutral

Electromed, Inc. announced it will release its fourth-quarter fiscal 2026 financial results on August 25, 2026. The announcement was made via a Business Wire press release from the company's New Prague, Minnesota headquarters.

Why it matters — ELMD watchers will learn the company's financial performance for the fourth quarter and full fiscal year 2026 when the results are published on that date.

FAQ

Frequently asked questions about ELMD stock

What is the ELMD stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Electromed, Inc. have a median 12-month price target of $40, with estimates ranging from $36 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELMD stock a buy right now?

Of the 3 analysts covering Electromed, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Electromed, Inc. 99 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELMD?

As at 22 Aug 2026, Electromed, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ELMD stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1.4% from the last close, and Ticker Nerd's factor model ranks Electromed, Inc. 99 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELMD stock forecast for 2030?

No analyst covering Electromed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $45 over the next 12 months.

How has ELMD stock performed over the past year?

Electromed, Inc. returned +107.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Electromed, Inc. do?

Electromed Inc. is a leading manufacturer and distributor of medical devices, primarily focusing on respiratory therapy solutions.

What is the latest news on ELMD?

The most recent item we track (Business Wire, 11 Aug 2026): "Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026". Electromed, Inc. announced it will release its fourth-quarter fiscal 2026 financial results on August 25, 2026. The announcement was made via a Business Wire press release from the company's New Prague, Minnesota headquarters.

Company

About Electromed, Inc.

Electromed Inc. is a leading manufacturer and distributor of medical devices, primarily focusing on respiratory therapy solutions. The company is renowned for its development of innovative airway clearance products, particularly the SmartVest Airway Clearance System, which assists patients with impaired breathing due to conditions like cystic fibrosis, bronchiectasis, and neuromuscular disorders. Electromed Inc. operates mainly within the healthcare sector, providing advanced solutions that improve patient outcomes and enhance quality of life for individuals with chronic respiratory conditions. The company's commitment to research and development helps it maintain a competitive edge, ensuring its products are at the forefront of medical technology. Electromed Inc.'s significant role in the market is underscored by its focus on expanding accessibility to its medical devices, through strategic partnerships and health care provider networks, thereby reinforcing its presence and influence in the respiratory care segment.

CEO Mr. James L. Cunniff · 177 employees · United States · https://smartvest.com